QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:PMD

Psychemedics (PMD) Stock Forecast, Price & News

$4.86
+0.01 (+0.21%)
(As of 06/8/2023 ET)
Compare
Today's Range
$4.76
$5.01
50-Day Range
$4.69
$5.60
52-Week Range
$4.67
$6.94
Volume
37,015 shs
Average Volume
6,624 shs
Market Capitalization
$27.80 million
P/E Ratio
N/A
Dividend Yield
5.76%
Price Target
N/A

PMD stock logo

About Psychemedics (NASDAQ:PMD) Stock

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, school, and personal drug testing services. The company was founded by Werner Baumgartner and Annette Baumgartner on September 24, 1986 and is headquartered in Acton, MA.

Receive PMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter.

PMD Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Psychemedics declares $0.07 dividend
Introducing MarketBeat All Access
Get real-time financial news and market data with MarketBeat All Access. Monitor your portfolio and the markets. Access our top stock picks, unbeatable research tools, best-in-class stock screeners, and proprietary research reports.
Psychemedics: Q2 Earnings Snapshot - Greenwich Time
See More Headlines

PMD Price History

PMD Company Calendar

Last Earnings
3/21/2023
Ex-Dividend for 4/10 Dividend
3/30/2023
Dividend Payable
4/10/2023
Ex-Dividend for 6/8 Dividend
5/24/2023
Today
6/08/2023
Dividend Payable
6/08/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PMD
Employees
139
Year Founded
1985

Profitability

Net Income
$-1,080,000.00
Pretax Margin
-6.62%

Debt

Sales & Book Value

Annual Sales
$24.59 million
Cash Flow
$0.39 per share
Book Value
$1.91 per share

Miscellaneous

Free Float
4,937,000
Market Cap
$27.52 million
Optionable
Not Optionable
Beta
0.60

Social Links


Key Executives

  • Raymond C. Kubacki
    Chairman, President & Chief Executive Officer
  • Charles M. Doucot
    Executive Vice President
  • Michael I. Schaffer
    Vice President-Laboratory Operations
  • William B. Norris
    Controller
  • Patrick J. Kinney
    Secretary













PMD Stock - Frequently Asked Questions

How have PMD shares performed in 2023?

Psychemedics' stock was trading at $4.9047 on January 1st, 2023. Since then, PMD shares have decreased by 1.9% and is now trading at $4.81.
View the best growth stocks for 2023 here
.

Are investors shorting Psychemedics?

Psychemedics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 11,700 shares, an increase of 24.5% from the April 30th total of 9,400 shares. Based on an average daily trading volume, of 6,800 shares, the short-interest ratio is presently 1.7 days. Approximately 0.3% of the company's stock are sold short.
View Psychemedics' Short Interest
.

When is Psychemedics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our PMD earnings forecast
.

How were Psychemedics' earnings last quarter?

Psychemedics Co. (NASDAQ:PMD) released its earnings results on Tuesday, March, 21st. The company reported ($0.12) earnings per share (EPS) for the quarter. The company earned $5.70 million during the quarter. Psychemedics had a negative trailing twelve-month return on equity of 13.52% and a negative net margin of 6.13%.

How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?

Psychemedics announced a quarterly dividend on Tuesday, May 9th. Shareholders of record on Thursday, May 25th will be given a dividend of $0.07 per share on Thursday, June 8th. This represents a $0.28 annualized dividend and a yield of 5.82%. The ex-dividend date is Wednesday, May 24th.
Read our dividend analysis for PMD
.

Is Psychemedics a good dividend stock?

Psychemedics (NASDAQ:PMD) pays an annual dividend of $0.28 per share and currently has a dividend yield of 5.97%. PMD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for PMD.

What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO?

6 employees have rated Psychemedics Chief Executive Officer Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among the company's employees.

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG).

What is Psychemedics' stock symbol?

Psychemedics trades on the NASDAQ under the ticker symbol "PMD."

Who are Psychemedics' major shareholders?

Psychemedics' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.95%), Ancora Advisors LLC (1.37%), BlackRock Inc. (1.38%) and Dimensional Fund Advisors LP (0.99%). Insiders that own company stock include Fred J Weinert, Michael I Schaffer, Peter Kamin and Raymond C Kubacki Jr.
View institutional ownership trends
.

How do I buy shares of Psychemedics?

Shares of PMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Psychemedics' stock price today?

One share of PMD stock can currently be purchased for approximately $4.81.

How much money does Psychemedics make?

Psychemedics (NASDAQ:PMD) has a market capitalization of $27.52 million and generates $24.59 million in revenue each year. The company earns $-1,080,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does Psychemedics have?

The company employs 139 workers across the globe.

How can I contact Psychemedics?

Psychemedics' mailing address is 289 GREAT ROAD Suite 200, ACTON MA, 01720. The official website for the company is www.psychemedics.com. The company can be reached via phone at (978) 206-8220 or via fax at 978-264-9236.

This page (NASDAQ:PMD) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -